A large trial has been launched in the UK exploring the use of stem cells for treating patients with Crohn’s disease. The radical treatment involves essentially “rebooting” a patient’s immune system and has been used successfully in the past for multiple sclerosis and some cancers.
Crohn’s disease is a chronic inflammatory bowel disease with no clearly understood cause. In severe cases it results in devastating and debilitating symptoms, and rates of diagnoses are increasing in Western countries. A variety of treatments are available to battle the disease, but they often do not work consistently and can have problematic side effects.
Widecells Group (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.